Abstract
During the last few years, poly(ADP-ribose)polymerase (PARP) proteins became a very popular target for anticancer treatment. Many PARP inhibitors have been generated and tested by pharmacological industry. However, most of them were designed to disrupt the DNA-dependent PARP1 protein activation pathway and were based on a competition with NAD for a binding site on PARP molecule and, therefore, on disruption of PARP-mediated enzymatic reaction. This limitation resulted in a discovery of mainly nucleotide-like PARP1 inhibitors which may target not only PARP, but also other pathways involving NAD and other nucleotides. Here, we describe a strategy for the identification of PARP inhibitors that target a different pathway, the histone H4-dependent PARP1 activation. Besides the identification of NAD competitors in a small-molecule collection, this approach allows finding novel classes of PARP inhibitors that specifically disrupt H4-based PARP activation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Satoh MS, Lindahl T (1992) Role of poly(ADP-ribose) formation in DNA repair. Nature 356(6367):356–358
Kim MY, Mauro S, Gevry N, Lis JT, Kraus WL (2004) NAD-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 119:803–814
Curtin NJ (2005) PARP inhibitors for cancer therapy. Expert Rev Mol Med 7:1–20
Virag L, Szabo C (2002) The therapeutic potential of Poly(ADP-Ribose) Polymerase inhibitors. Pharmacol Rev 54:375–429
Haince JF, Poirier GG, Kirkland JB (2003) Nonisotopic methods for determination of poly(ADP-ribose) levels and detection of poly(ADP-ribose) polymerase. Curr Protoc Cell Biol, 18.7.1–18.7.26
Ritter CA et al (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:4909–4919
Luger K, Rechsteiner TJ, Richmond TJ (1999) Expression and purification of recombinant histones and nucleosome reconstitution. Methods Mol Biol 119:1–16
Luger K, Rechsteiner TJ, Richmond TJ (1999) Preparation of nucleosome core particle from recombinant histones. Methods Enzymol 304:3–19
Monti D et al (1994) Cell death protection by 3-aminobenzamide and other poly(ADP- ribose)polymerase inhibitors: different effects on human natural killer and lymphokine activated killer cell activities. BBRC 199:525–530
Schlicker A et al (1999) 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int J Radiat Biol 75:91–96
Banasik M et al (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267:1569–1575
Zhang JH et al (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4(2):67–73
Iversen PW et al (2006) A comparison of assay performance measures in screening assays: signal window, Z’ factor, and assay variability ratio. J Biomol Screen 11(3):247–252
Gottipati P et al (2010) Poly(ADP-Ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 70:5389–5398
Acknowledgments
We thank Dr. M. Einarson of the FCCC Translational Facility for her advice and assistance with small-molecule collection screening experiments, Dr. I. Serebriiskii for helpful discussions, and Dr. M. Robinson for BT474 and HR6 breast cancer cell lines. The research was supported by grants from the National Institutes of Health (R01 DK082623) to A.V.T.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kotova, E., Pinnola, A.D., Tulin, A.V. (2011). Small-Molecule Collection and High-Throughput Colorimetric Assay to Identify PARP1 Inhibitors. In: Tulin, A. (eds) Poly(ADP-ribose) Polymerase. Methods in Molecular Biology, vol 780. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-270-0_29
Download citation
DOI: https://doi.org/10.1007/978-1-61779-270-0_29
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-269-4
Online ISBN: 978-1-61779-270-0
eBook Packages: Springer Protocols